Clinical studies have demonstrated that sildenafil, in doses higher than those found in Cenforce 50, can effectively lower pulmonary artery pressure and improve exercise capacity in PAH patients. For instance, the medication is marketed under the brand name Revatio when used for PAH. Revatio contains sildenafil but is specifically dosed and formulated for treating PAH. The standard dosing for PAH is higher than that used for ED, typically around 20 mg three times a day.